PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

被引：0

作者：

Wasserman, R. L. ^{[1
]}

Melamed, I. ^{[2
]}

Stein, M. ^{[3
]}

Rubinstein, A. ^{[4
,5
]}

Puck, J. ^{[6
]}

Gupta, S. ^{[7
]}

Engl, W. ^{[8
]}

Leibl, H. ^{[8
]}

McCoy, B. ^{[8
]}

Gelmont, D. ^{[9
]}

Schiff, R. I. ^{[9
]}

机构：

[1] DallasAllergyImmunology, Dallas, TX USA

[2] IMMUNOe, Centennial, CO USA

[3] Allergy Associates Palm Beaches, N Palm Beach, FL USA

[4] Albert Einstein Coll Med, Bronx, NY 10467 USA

[5] Montefiore Hosp, Bronx, NY USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Univ Calif Irvine, Irvine, CA USA

[8] Baxter BioSci, Vienna, Austria

[9] Baxter BioSci, Westlake Village, CA USA

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2012年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：136 / 136

页数：1

共 50 条

[1] PHARMACOKINETICS OF HUMAN IMMUNOGLOBULIN G, 10%, ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF PATIENTS WITH PRIMARY IMMUNODEFICIENCY
Stein, M.
Wasserman, R. L.
Melamed, I.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 156 - 157
[2] Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency (PI)
Stein, Mark
Wasserman, Richard
Melamed, Isaac
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
Gelmont, David
Schiff, Richard
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 364 - 365
[3] Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)
Stein, M.
Wasserman, R. L.
Melamed, I.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB14 - AB14
[4] PHARMACOKINETICS (PK) OF HUMAN IMMUNOGLOBULIN 10% (IGG) ADMINISTERED INTRAVENOUSLY (IGIV), SUBCUTANEOUSLY (IGSC) OR FACILITATED SUBCUTANEOUSLY WITH RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS (PTS) WITH PRIMARY IMMUNODEFICIENCY DISEASE (PIDD)
Wasserman, R. L.
Melamed, I.
Stein, M.
Rubinstein, A.
Engl, W.
Leibl, H.
McCoy, B.
Gelmont, D.
Schiff, R. I.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A94 - A94
[5] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY): SUBSET OF STUDY PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
Wasserman, R. L.
Melamed, I.
Stein, M.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 155 - 156
[6] Pharmacokinetics (PK) of Human Immunoglobulin 10% Administered Subcutaneously Alone or Following Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients
Rubinstein, A.
Wasserman, R. L.
Melamed, I.
Stein, M.
McCoy, B.
Engl, W.
Leibl, H.
Gelmont, D.
Schiff, R. I.
Grossman, W. J.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB213 - AB213
[7] TOLERABILITY AND EFFICACY OF FACILITATED-SUBCUTANEOUS INFUSION OF HUMAN IMMUNOGLOBULIN G, 10%, AND RECOMBINANT HUMAN HYALURONIDASE (IGHY) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PI)
Stein, M.
Wasserman, R. L.
Melamed, I.
Rubinstein, A.
Puck, J.
Gupta, S.
Engl, W.
Leibl, H.
McCoy, B.
Gelmont, D.
Schiff, R. I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 135 - 136
[8] Safety and Pharmacokinetics (Pk) of Recombinant Human Hyaluronidase (RHUPH20)-Facilitated Subcutaneous (SC) Infusion of Immunoglobulin G (IGSC) (IGHY) in Adult Patients with Primary Immunodeficiencies (PI): Extension Study of a Phase 3 Pivotal Trial
Melamed, Isaac
Wasserman, Richard L.
Stein, Mark R.
Rubinstein, Arye
Puck, Jennifer
Gupta, Sudhir
Engl, Werner
Leibl, Heinz
Yel, Leman
Schiff, Richard I.
JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 379 - 379
[9] Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients
Gelmont, D.
Wasserman, R. L.
Melamed, I.
Stein, M.
Rubinstein, A.
McCoy, B.
Engl, W.
Leibl, H.
Schiff, R. I.
Grossman, W. J.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB15 - AB15
[10] Modeled Economic Impact of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% with Recombinant Human Hyaluronidase (IGHy) or Intravenous Immunoglobulin (IGIV) in Primary Immunodeficiency (PI) Patients
Iyer, Ravi
Luo, Michelle
Li-McLeod, Josephine
JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 397 - 397

← 1 2 3 4 5 →